Comparison · NCT00683800-68954c02
DVS SR 100 mg vs Placebo: Number of Participants With Hepatic Events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. DVS SR 100 mg vs Placebo: Number of Participants With Hepatic Events. Trial comparisons, record NCT00683800-68954c02. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00683800-68954c02
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00188 | 0.000515 | 0.00681 | wilson | |
| Risk in group 2 | 0.0019 | 0.000522 | 0.00691 | wilson | |
| Risk difference, group 1 minus group 2 | -0.000025 | -0.00521 | 0.0051 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.987 | 0.139 | 6.99 | log | |
| Odds ratio, group 1 over group 2 | 0.987 | 0.139 | 7.02 | log | |
| Number needed to treat, for one fewer participant with the outcome on DVS SR 100 mg than on Placebo | 40,100 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | DVS SR 100 mg | Desvenlafaxine Succinate Sustained Release (DVS SR) 100 milligram (mg) tablets daily until Day 365 or early withdrawal. | 2 | 1,066 | OG000 |
| Group 2 | Placebo | Matching placebo tablets daily until Day 365 or early withdrawal. | 2 | 1,052 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- OTHER_PRE_SPECIFIED
- Title
- Number of Participants With Hepatic Events
- Description
Hepatic events were defined as incidence of increased Liver Function Test (AST \[aspartate aminotransferase\] or ALT \[alanine aminotransferase\]) levels greater than 5 times the ULN (upper limit of normal).
- Time frame
- Baseline up to Month 12
- Population
- Safety population included all randomized participants who received at least 1 dose of study medication.
Source ClinicalTrials.gov
Trial
- Title
- Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women
- NCT number
- NCT00683800
- Phases
- PHASE3
- Conditions
- Vasomotor Symptoms
- Interventions
- desvenlafaxine succinate (DVS) SR, Placebo
- Lead sponsor
- Pfizer
- Results first posted
- 2011-08-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00683800?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00683800-68954c02